STUDY QUESTION: Does addition of choriogonadotropin beta (recombinant CG beta) to follitropin delta increase the number of good-quality blastocysts following ovarian stimulation in a long GnRH agonist protocol? SUMMARY ANSWER: At the doses investigated, the addition of CG beta reduced the number of intermediate follicles and related down-stream parameters including the number of oocytes and blastocysts. WHAT IS KNOWN ALREADY: CG beta is a novel recombinant hCG (rhCG) molecule expressed by a human cell line (PER.C6®) and has a different glycosylation profile compared to urinary hCG or rhCG derived from a Chinese Hamster Ovary (CHO) cell line. In the first-in-human trial, the CG beta pharmacokinetics were similar between men and women. In women, the AUC and the peak serum concentration (Cmax) increased approximately dose proportionally following single and multiple daily doses. In men, a single dose of CG beta provided higher exposure with a longer half-life and proportionately higher testosterone production than CHO cell-derived rhCG. STUDY DESIGN, SIZE, DURATION: This placebo-controlled, double-blind, randomized trial (RAINBOW) was conducted in five European countries to explore the efficacy and safety of CG beta as add-on treatment to follitropin delta in women undergoing ovarian stimulation in a long GnRH agonist protocol. Randomization was stratified by centre and age (30-37 and 38-42 years). The primary endpoint was the number of good-quality blastocysts (Grade 3 BB or higher). Subjects were randomized to receive either placebo or 1, 2, 4, 8 or 12 µg CG beta added to the daily individualized follitropin delta dose during ovarian stimulation. PARTICIPANTS/MATERIALS, SETTING, METHODS: In total, 620 women (30-42 years) with anti-Müllerian hormone (AMH) levels between 5 and 35 pmol/l were randomized in equal proportions to the six treatment groups and 619 subjects started treatment. All 619 subjects were treated with an individualized dose of follitropin delta determined based on AMH (Elecsys AMH Plus Immunoassay) and body weight. Triggering with rhCG was performed when 3 follicles were ≥17 mm but no more than 25 follicles ≥12 mm were reached. MAIN RESULTS AND THE ROLE OF CHANCE: The demographic characteristics were comparable between the six treatment groups and the overall mean age, body weight and AMH were 35.6 ± 3.3 years, 65.3 ± 10.7 kg and 15.3 ± 7.0 pmol/l, respectively. The incidence of cycle cancellation (range 0-2.9%), total follitropin delta dose (mean 112 µg) and duration of stimulation (mean 10 days) were similar across the groups. At stimulation Day 6, the number and size of follicles was similar between the treatment groups, whereas at the end-of-stimulation dose-related decrease of the intermediate follicles between 12 and 17 mm was observed in comparison to the placebo group. In contrast, the number of follicles ≥17 mm was similar between the CG beta dose groups and the placebo group. A reduced number of intermediate follicles (12 to 17 mm) and fewer oocytes (mean range 9.7 to 11.2) were observed for all doses of CG beta compared to the follitropin delta only group (mean 12.5). The mean number of good-quality blastocysts was 3.3 in the follitropin delta group and ranged between 2.1 and 3.0 across the CG beta groups. The incidence of transfer cancellation was higher in the 4, 8 and 12 µg group, mostly as no blastocyst was available for transfer. In the group receiving only follitropin delta, the ongoing pregnancy rate (10-11 weeks after transfer) was 43% per started cycle versus 28-39% in CG beta groups and 49% per transfer versus 38-50% in the CG beta groups. There was no apparent effect of CG beta on the incidence of adverse events, which was 48.1% in the placebo group and 39.6-52.3% in the CG beta dose groups. In line with the number of collected oocytes, the overall ovarian hyperstimulation syndrome incidence remained lower following follitropin delta with CG beta (2.0-10.3%) compared with follitropin delta only treatment (11.5%). Regardless of the dose, CG beta was safe and well-tolerated with low risk of immunogenicity. LIMITATIONS, REASONS FOR CAUTION: The effect of the unique glycosylation of CG beta and its associated potency implications in women were not known prior to this trial. Further studies will be needed to evaluate optimal doses of CG beta for this and/or different indications. WIDER IMPLICATIONS OF THE FINDINGS: The high ongoing pregnancy rate in the follitropin delta group supports the use of individualized follitropin delta dosing in a long GnRH agonist protocol. The addition of CG beta reduced the presence of intermediate follicles with the investigated doses and negatively affected all down-stream parameters. Further clinical research will be needed to assess the optimal dose of CG beta in the optimal ratio to follitropin delta to develop this novel combination product containing both FSH and LH activity for ovarian stimulation. STUDY FUNDING/COMPETING INTEREST(S): The study was funded by Ferring Pharmaceuticals, Copenhagen, Denmark. B.M. and P.L. are employees of Ferring Pharmaceuticals. M.F.S., H.V., C.Y.A., M.F., C.B., A.P. and Y.K. have received institutional clinical trial fees from Ferring Pharmaceuticals. C.B. has received payments for lectures from Organon, Ferring Pharmaceuticals, Merck A/S and Abbott. M.F.S. has received payment for lectures from Ferring Pharmaceuticals. Y.K. has received payment for lectures from Merck and travel support from Gedeon Richter. H.V. has received consulting fees from Oxo and Obseva and travel support from Gedeon Richter, Ferring Pharmaceuticals and Merck. C.Y.A. has received payment for lectures from IBSA, Switzerland. M.F and C.Y.A. were reimbursed as members of the Data Monitoring Board in this trial. M.F. has an issued patent about unitary combination of FSH and hCG (EP1633389). TRIAL REGISTRATION NUMBER: 2017-003810-13 (EudraCT Number). TRIAL REGISTRATION DATE: 21 May 2018. DATE OF FIRST PATIENT’S ENROLMENT: 13 June 2018.

Assisted Conception Unit Guy's Hospital London UK

Centre for Reproductive Medicine Universitair Ziekenhuis Brussel Brussels Belgium

Departament of Surgery Universidad de Sevilla Seville Spain

Department of Molecular Biology and Biochemical Engineering Universidad Pablo de Olavide Seville Spain

Fertility Clinic Rigshospitalet Copenhagen University Hospital Copenhagen Denmark

Fundacion IVI Instituto Investigación Sanitaria La Fe Valencia Spain

Global Biometrics Ferring Pharmaceuticals Copenhagen Denmark

GynePro Medical Group Bologna Italy

IVF CUBE Prague Czech Republic

IVI RMA Seville Seville Spain

Laboratory of Reproductive Biology Copenhagen University Hospital and Faculty of Health Science Copenhagen University Copenhagen Denmark

Reproductive Medicine and Maternal Health Ferring Pharmaceuticals Copenhagen Denmark

Zobrazit více v PubMed

Al-Inany HG, Abou-Setta AM, Aboulghar M.  Gonadotrophin-releasing hormone antagonist for assisted conception: a cochrane review. Reprod Biomed Online  2007;14:640–649. PubMed

Alpha Scientists in Reproductive Medicine and ESHRE Special Interest Group of Embryology. The Istanbul consensus workshop on embryo assessment: proceedings of an expert meeting. Hum Reprod  2011;26:1270–1283. PubMed

Andersen AN, Devroey P, Arce JC.  Clinical outcome following stimulation with highly purified hMG or recombinant FSH in patients undergoing IVF: a randomized assessor-blind controlled trial. Hum Reprod  2006;21:3217–3227. PubMed

Arce JC, Smitz J.  Live-birth rates after HP-hMG stimulation in the long GnRH agonist protocol: association with mid-follicular hCG and progesterone concentrations, but not with LH concentrations. Gyn Endocrinol  2013;29:46–50. PubMed PMC

Ascoli M, Fanelli F, Segaloff DL.  The lutropin/choriogonadotropin receptor, a 2002 perspective. Endocr Rev  2002;23:141–174. PubMed

Bagchus W, Wolna P, Uhl W.  Single-dose pharmacokinetic study comparing the pharmacokinetics of recombinant human chorionic gonadotropin in healthy Japanese and Caucasian women and recombinant human chorionic gonadotropin and urinary human chorionic gonadotropin in healthy Japanese women. Reprod Med Biol  2017;17:52–58. PubMed PMC

Broksø Kyhl LE, Hesse C, Larsson P, Bruzelius K, Mannaerts B.  First-in-human trial assessing the pharmacokinetic-pharmacodynamic profile of a novel recombinant human chorionic gonadotropin in healthy women and men of reproductive age. Clin Transl Sci  2021;14:1590–1599. PubMed PMC

Casarini L, Santi D, Brigante G, Simoni M.  Two hormones for one receptor: evolution, biochemistry, actions, and pathophysiology of LH and hCG. Endocr Rev  2018;39:549–592. PubMed

Cole LA.  New discoveries on the biology and detection of human chorionic gonadotropin. Reprod Biol Endocrinol  2009;7:8. PubMed PMC

Cole LA.  Biological functions of hCG and hCG-related molecules. Reprod Biol Endocrinol  2010;8:102–116. PubMed PMC

Conti M, Harwood JP, Hsueh AJ, Dufau ML, Catt KJ.  Gonadotropin induced loss of hormone receptors and desensitization of adenylate cyclase in the ovary. J Biol Chem  1976;251:7729–7731. PubMed

Cortvrindt RG, Hu Y, Liu J, Smitz JEJ.  Timed analysis of the nuclear maturation of oocytes in early preantral mouse follicle culture supplemented with recombinant gonadotropin. Fert Steril  1998;70:1114–1125. PubMed

Cottingham I, Plaksin D, White RB. Ferring International Center SA. 2011. Pharmaceutical preparation comprising recombinant hCG, PCT/GB2010/001854.

EMA-CHMP. Guideline on Immunogenicity Assessment of Therapeutic Proteins. 2017. https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-immunogenicity-assessment-therapeutic-proteins-revision-1_en.pdf.

European Orgalutran Study Group, Borm G, Mannaerts B.  Treatment with the gonadotrophin releasing hormone antagonist ganirelix in women undergoing ovarian stimulation with recombinant follicle stimulating hormone is effective, safe and convenient: results of a controlled, randomized, multicenter trial. Hum Reprod  2000;15:1490–1498. PubMed

Fernández-Sánchez M, Visnova H, Yuzpe A, Klein BM, Mannaerts B, Arce J-C; ESTHER-1 and ESTHER-2 Study Group. Individualization of the starting dose of follitropin delta reduces the overall OHSS risk and/or the need for additional preventive interventions: cumulative data over three stimulation cycles. Reprod Biomed Online  2019;38:528–537. PubMed

Filicori M, Cognigni GE, Gamberini E, Parmegiani L, Troilo E, Roset B.  Efficacy of low-dose human chorionic gonadotropin alone to complete controlled ovarian stimulation. Fert Steril  2005;84:394–401. PubMed

Filicori M, Cognigni GE, Tabarelli C, Pocognoli P, Spettoli D, Taraborelli S, Spettoli D, Ciampaglia W.  Stimulation and growth of antral follicles by selective LH activity administration in women. J Clin Endocrinol. Metab  2002;87:1156–1161. PubMed

Filicori M, Cognigni GE, Taraborrelli S, Spettoli D, Ciampaglia W, Tabarelli de Fatis C, Pocognoli P, Cantelli B, Boschi S.  Luteinizing hormone activity in menotropins optimizes folliculogenesis and treatment in controlled ovarian stimulation. J Clin Endocrinol Metab  2001;86:337–343. PubMed

Franks S, Hardy K.  Androgen action in the ovary. Front Endocrinol (Lausanne)  2018;9:452. PubMed PMC

Gardner DK, Schoolcraft WB.  In vitro culture of human blastocysts. In: Jansen R,, Mortimer D (eds). Towards Reproductive Certainty. The Plenary Proceedings of the 11th World Congress on in Vitro Fertilization and Human Reproductive Genetics. New York: The Parthenon Publishing Group, 1999, 378–388.

Golan A, Ron-el R, Herman A, Soffer Y, Weinraub Z, Caspi E.  Ovarian hyperstimulation syndrome: an update review. Obstet Gynecol Surv  1989;44:430–440. PubMed

Hillier SG, Tetsuka M.  Role of androgens in follicle maturation and atresia. Baillieres Clin Obstet Gynaecol  1997;11:249–260. PubMed

Hugues JN, Soussis J, Calderon I, Balasch J, Anderson RA, Romeu A; on behalf of the Recombinant LH Study Group. Does the addition of recombinant LH in WHO group II anovulatory women over-responding to FSH treatment reduce the number of developing follicles? A dose-finding study. Hum Reprod  2005;20:629–635. PubMed

Jeppesen JV, Kristensen SG, Nielsen ME, Humaidan P, Dal Canto M, Fadini R, Schmidt KT, Ernst E, Yding Andersen C.  LH-receptor gene expression in human granulosa and cumulus cells from antral and preovulatory follicles. J Clin Endorinol Metab  2012;97:1524–1531. PubMed PMC

Koechling W, Plaksin D, Croston GE, Jeppesen JV, Macklon KT, Andersen CY.  Comparative pharmacology of a new recombinant FSH expressed by a human cell line. Endocr Connect  2017;6:297–305. PubMed PMC

Loumaye E, Engrand P, Shoham Z, Hillier SG, Baird DT; on behalf of the Recombinant LH Study Group. Clinical evidence for an LH ‘ceiling’ effect induced by administration of recombinant human LH during the late follicular phase of stimulated cycles in World Health Organization type I and type II anovulation. Hum Reprod  2003;18:314–322. PubMed

Mannaerts B, Uilenbroek J, Schot P, De Leeuw R.  Folliculogenesis in hypophysectomized rats after treatment with recombinant human follicle-stimulating hormone. Biol Reprod  1994;51:72–81. PubMed

McGee EA, Hsueh AJ.  Initial and cyclic recruitment of ovarian follicles. Endocr Rev  2000;21:200–214. PubMed

Menon KMJ, Menon B.  Structure, function and regulation of gonadotropin receptors—a perspective. Mol Cell Endocrinol  2012;356:88–97. PubMed PMC

Menon KMJ, Munshi UM, Clouser CL, Nair AK.  Regulation of luteinizing hormone/human chorionic gonadotropin receptor expression: a perspective. Biol Reprod  2004;70:861–866. PubMed

Nyboe Andersen A, Nelson SM, Fauser BCJM, García-Velasco JA, Klein BM, Arce J-C; ESTHER-1 Study Group.  Individualized versus conventional ovarian stimulation for in vitro fertilization: a multicenter, randomized, controlled, assessor-blinded, phase 3 noninferiority trial. Fertil Steril  2017;107:387–396. PubMed

Pierce JG, Parsons TF.  Glycoprotein hormones: structure and function. Annu Rev Biochem  1981;50:465–495. PubMed

Shankar G, Devanarayan V, Amaravadi L, Barrett Y, Bowsher R, Finco-Kent D, Fiscella M, Gorovits B, Kirschner S, Moxness M.  Recommendations for the validation of immunoassays used for detection of host antibodies against biotechnology products. J Pharm Biomed Anal  2008;8:1267–1281. PubMed

Thuesen LL, Loft A, Egeberg AN, Smitz J, Petersen JH, Nyboe Andersen A.  A randomized controlled dose-response pilot study of addition of hCG to recombinant FSH during controlled ovarian stimulation for in vitro fertilization. Hum Reprod  2012;27:3074–3084. PubMed

Thuesen LL, Smitz J, Loft A, Nyboe Andersen A.  Endocrine effects of hCG supplementation to recombinant FSH throughout controlled ovarian stimulation for IVF: a dose-response study. Clin Endocrinol  2013;79:708–715. PubMed

Trinchard-Lugan I, Khan A, Porchet HC, Munafo A.  Pharmacokinetics and pharmacodynamics of recombinant human chorionic gonadotrophin in healthy male and female volunteers. Reprod Biomed Online  2002;4:106–115. PubMed

Yding Andersen C, Ziebe S, Guoliang X, Byskov AG.  Requirements for human chorionic gonadotropin and recombinant human luteinizing hormone for follicular development and maturation. J Ass Reprod Genet  1999;16:425–430. PubMed PMC

Ziebe S, Lundin K, Janssens R, Helmgaard L, Arce J-C; MERIT (Menotrophin vs Recombinant FSH in vitro Fertilisation Trial) Group. Influence of ovarian stimulation with HP-hMG or recombinant FSH on embryo quality parameters in patients undergoing IVF. Hum Reprod  2007;22:2404–2413. PubMed